Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2022-05-31 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Mee
Report Publication Announcement Classification · 1% confidence The document is very short (1771 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k31052022_DC_isa.pdf*". This structure—a brief announcement pointing to an attached or linked external report (in this case, a Form 6-K filed with the ISA and TASE)—fits the definition of a Report Publication Announcement (RPA). It is not the full 6-K report itself, but the notice of its publication. Since RPA is a specific category for such announcements, it is preferred over the general fallback RNS.
2022-05-31 English
Financial statements for the three month period ended March 31, 2022
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains unaudited condensed consolidated financial statements for the three-month period ended March 31, 2022. Since it provides comprehensive financial data (balance sheets, statements of operations, cash flows) for an interim period, it is classified as an Interim/Quarterly Report (IR). Q1 2022
2022-05-28 English
Financial statements for the three month period ended March 31, 2022
Report Publication Announcement Classification · 1% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed under Israeli Securities Authority regulations. Crucially, it contains the line: 'Attached hereto is a report on *6-k* *6k27052022_DC_isa.pdf*'. The document itself is very short (1885 characters) and serves only to announce the attachment of a formal report (a 6-K filing, which is typically an interim report for foreign private issuers). According to Rule 2, when a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). While it relates to an Interim Report (IR), the document's function here is the announcement itself.
2022-05-28 English
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing used by Foreign Private Issuers to report material information that is made public in their home country or required to be filed with a foreign securities exchange. This type of filing is generally used for current reports that do not fit neatly into the standard domestic SEC forms (like 8-K). Since the provided definitions do not have a specific code for Form 6-K, and this document is a current report announcing a material event (receiving a grant), it falls best under the 'Regulatory Filings' fallback category (RNS), as it is a general regulatory announcement not covered by the more specific categories like ER, DIV, or CAP, although it does relate to financing/grants. However, given the context of SEC filings, RNS is the most appropriate general regulatory category when a specific SEC form code is missing from the provided list. The document is substantial (7271 chars) and contains the full announcement, not just a notice of publication, ruling out RPA.
2022-05-25 English
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
Report Publication Announcement Classification · 1% confidence The document is very short (1771 characters) and explicitly states, "Attached hereto is a report on *6-k* *6k25052022_DC_isa.pdf*". This structure—a brief announcement referencing an attached or linked primary document (in this case, an SEC Form 6-K, which is a report of material events for foreign private issuers)—fits the definition of a Report Publication Announcement (RPA). It is not the full 6-K report itself, but the notice of its publication. Since RPA is a specific category for such announcements, it is preferred over the general fallback RNS.
2022-05-25 English
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
Board/Management Information Classification · 1% confidence The document is explicitly identified as a "Form 6-K" filed with the SEC. The content announces the appointment of a new member to the Board of Directors, Dr. Roger J. Pomerantz, and includes the related press release as Exhibit 99.1. This type of announcement, concerning changes in the board of directors or senior management, directly corresponds to the definition of Board/Management Information (MANG). Although Form 6-K is a general filing form for foreign private issuers, the specific subject matter dictates the classification.
2022-05-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.